ArticleExperimental and therapeutic medicine2026
Postmenopausal complete hydatidiform mole: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complete hydatidiform mole (CHM) cases occurring in the postmenopausal period are quite rare and may be delayed in diagnosis. In the present study, the case reported is of a 55-year-old postmenopausal woman (menopausal for 5 years) who presented with painless postmenopausal bleeding in March 2025, ongoing for ~1 month and was diagnosed with CHM. Transvaginal ultrasonography showed endometrial thickness of 28-mm and serum β-human chorionic gonadotropin (β-hCG) level of 187,240 mIU/ml. After ultrasound-guided curettage, the diagnosis of CHM was confirmed in histopathological examination. Since the patient was postmenopausal, laparoscopic hysterectomy and bilateral salpingo-oophorectomy were performed. Postoperative follow-up was performed in accordance with International Federation of Gynecology and Obstetrics (FIGO) guidelines; the protocol used (weekly β-hCG until negative, then monthly for 6 months) is fully consistent with the 2025 FIGO update. By December 2025, the patient had successfully finished the suggested follow-up regimen and was still in total remission with no signs of recurrence. In patients with abnormal uterine bleeding and high β-hCG levels in the postmenopausal period, gestational trophoblastic diseases should be considered in the differential diagnosis. Malignant complications can be prevented with early diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.